The estimated Net Worth of Garrett Winslow is at least $52.5 Thousand dollars as of 3 December 2021. Mr Winslow owns over 2,000 units of Galecto stock worth over $52,480 and over the last 5 years he sold GLTO stock worth over $0.
Sign up
Mr Winslow GLTO stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Galecto stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of GLTO stock worth $4,960 on 3 December 2021.
The largest trade he's ever made was exercising 6,250 units of Galecto stock on 19 November 2020 worth over $82,000. On average, Mr trades about 1,281 units every 47 days since 2020. As of 3 December 2021 he still owns at least 4,000 units of Galecto stock.
You can see the complete history of Mr Winslow stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Garrett Winslow biography
Garrett Winslow is the Sr. VP & Gen. Counsel at Galecto.
How old is Mr Winslow?
Mr Winslow is 42, he's been the Sr. VP & Gen. Counsel of Galecto since . There are 4 older and no younger executives at Galecto. The oldest executive at Galecto Inc. is Prof. Bertil Lindmark M.D., Ph.D., 66, who is the Chief Medical Officer.
What's Mr Winslow's mailing address?
Garrett's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Insiders trading at Galecto
Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong, and Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.
What does Galecto do?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
What does Galecto's logo look like?
Complete history of Mr Winslow stock trades at Spring Bank Pharmaceuticals and Galecto
Galecto executives and stock owners
Galecto executives and other stock owners filed with the SEC include:
-
Dr. Hans T. Schambye,
Co-Founder, Pres, CEO & Director -
Prof. Bertil Lindmark M.D., Ph.D.,
Chief Medical Officer -
Anders Pedersen,
Chief Operating Officer -
Dr. Stephanie Oestreich Ph.D.,
Chief Bus. Officer -
Garrett Winslow,
Sr. VP & Gen. Counsel -
Jonathan P. Freve CPA, CPA,
Chief Financial Officer -
Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP,
Co-Founder & Member of the Clinical Advisory Board - IPF -
Dr. Hakon Leffler,
Co-Founder -
Ulf J. Nilsson,
Co-Founder -
Advisors Llc Orbi Med Genes...,
-
Holdings A/S Novo,
10% owner -
Carl Goldfischer,
-
Anders Pedersen,
Chief Operating Officer -
Hans T. Schambye,
Chief Executive Officer -
Stephan Christgau,
Director -
Advisors Llc Orbi Med Advis...,
-
Bertil Lindmark,
Chief Medical Officer -
Jonathan Freve,
Chief Financial Officer -
Chau Quang Khuong,
Director -
Stephanie Oestreich,
Chief Business Officer -
Jayson Donald Alexander Dallas,
-
Amit Munshi,
-
Anne Prener,
-
David Shapiro,
-
Garrett Winslow,
General Counsel